More importantly, the second gene mutations, e.g., TP53 mutation, RB1 splice site mutation, and FBXW7 mutation (Arg441Phe) loss, also occur in the histological conversion from immunotherapy-resistant NSCLC into SCLC, as described by Iams et al. Here, TP53 is linked to non-small cell lung carcinoma.